フジワラ アツシ
  藤原 篤之
   所属   川崎医療福祉大学  リハビリテーション学部 視能療法学科
   職種   助教
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.
掲載誌名 正式名:Japanese journal of ophthalmology
略  称:Jpn J Ophthalmol
ISSNコード:16132246/00215155
掲載区分国外
巻・号・頁 61(2),150-158頁
著者・共著者 Hosokawa Mio, Morizane Yuki, Hirano Masayuki, Kimura Shuhei, Kumase Fumiaki, Shiode Yusuke, Doi Shinichiro, Toshima Shinji, Hosogi Mika, Fujiwara Atsushi, Mitsuhashi Toshiharu, Shiraga Fumio
発行年月 2017/03
概要 PURPOSE:To evaluate the 1-year treatment outcomes of intravitreal aflibercept injections (IVA) using a treat-and-extend regimen for polypoidal choroidal vasculopathy (PCV).METHODS:Thirty-seven eyes with treatment-naive PCV treated with IVA using a treat-and-extend regimen for 1 year were reviewed retrospectively. The main outcome measures were changes in the best-corrected visual acuity (BCVA) and central retinal thickness (CRT), and the treatment interval at 1 year. The predictive factors for patients who could not continue to extend the treatment interval because of poor response to IVA or recurrence were analyzed.RESULTS:The mean logarithm of the minimum angle of resolution BCVA improved from 0.37 at baseline to 0.21 at 1 year (P < 0.001). The mean CRT decreased from 342.3 μm at baseline to 196.6 μm at 1 year (P < 0.001). The mean treatment interval was 9.7 weeks at 1 year (4 weeks in 11 eyes [29.7%], 6 weeks in 1 eye [2.7%], 8 weeks in 2 eyes [5.4%], 10 weeks in 1 eye [2.7%], and 12 weeks in 22 eyes [59.5%]). A larger number of polypoidal lesions at baseline was predictive for patients who could not continue to extend the treatment interval.CONCLUSIONS:IVA using a treat-and-extend regimen is effective for improving BCVA and CRT in eyes with PCV.
DOI 10.1007/s10384-016-0492-7
PMID 27928695